Urine analysis enables cardiovascular risk assessment
Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide. A vast amount of deaths and disabilities caused by CAD could be cut by an early diagnosis, enabling effective individual actions for preventing clinical events like acute myocardial infarction.
Researchers of mosaiques diagnostics, the British Heart Foundation (Glasgow, UK), and Baker Heart Research Institute (Melbourne, Australia) examined a total of 370 patients in an international blinded clinical study. The consortium established a diagnostic urine test distinguishing between presence and absence of CAD with sensitivity of 98% and specificity of 83%. Mosaiques' proprietary CE-MS technology (capillary electrophoresis coupled to mass spectrometry) enabled not only the successful identification of CAD patients, but also suggests the possibility of monitoring the effects of therapeutic interventions. This non invasive and precise diagnostic procedure provides tremendous benefits for patients with significantly increased risk of cardiovascular complications, such as patients with type II diabetes and the elderly in personalized medicine. According to the company, the technology already proved high advancement and impact on drug evaluation during clinical trials by a detailed assessment of drug effects on the vascular and - considering mosaiques' further diagnostics - renal architecture.
Original publication: "Urinary proteomic biomarkers in coronary artery disease."; Molecular & Cellular Proteomics 2007.
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!

Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Last viewed contents

Brain stimulation could help treat Alzheimer’s disease - Study discovers brain network that alleviates symptoms when stimulated
Sartorius reviews fiscal 2008 - Different outlook for the two Group divisions
Sanofi licenses worldwide rights on regenerative treatment for osteoarthritis and cartilage disorders from Scil Technology
Roche Diagnostics Announces Dan Zabrowski as New Head of Roche Applied Science
LUX biotechnology wins the Pfizer Award for Innovation
Bausch & Lomb and Galapagos sign agreement to collaborate on ophthalmic disease research

And the winner is …. cancer research
Eurofins expands its footprint in Asia with the acquisition of Lab Frontier in South Korea

Seramun Diagnostica GmbH - Heidesee, Germany
Stem Cell Sciences and the University of Edinburgh announce new technology transfer agreement
